Heart Matters



  Guest: Paul Sorajja, MD 


  
    TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.

Updates from ACC 2023: Examining Transcatheter Repair Study Data


Exploring the Use of AI to Detect HFpEF


Guest: Paul Sorajja, MD 


  
    TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its re



  Host: Javed Butler, MD <br>

  Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S. <br>


  
    <p>For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.</p>